Allergy and Airway: Allergy - Asthma |

Associations Between Asthma Control and Health-Related Quality of Life Among Patients With Allergic Asthma on Inhaled Corticosteroids and Long-Acting Beta Agonists Combination Therapy FREE TO VIEW

Brandee Paknis, PharmD; Lulu Lee, PhD; Engels Obi, PhD; Abhishek Kavati, PhD; Bradley Chipps, MD
Author and Funding Information

Novartis Pharmaceuticals Corporation, East Hanover, NJ

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):5A. doi:10.1016/j.chest.2016.08.008
Text Size: A A A
Published online

SESSION TITLE: Allergy - Asthma

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: To examine level of asthma control and associations with health-related quality of life (HRQoL) among patients with allergic asthma on inhaled corticosteroids (ICS) and long-acting beta agonists (LABA) combination therapy.

METHODS: Data from the 2011-2013 US National Health and Wellness Survey, a nationally representative, self-administered, internet-based survey of adults (≥18 years old), were used to identify allergic asthma patients currently on ICS and LABA combination therapy (N=1,923). Allergic asthma was defined by a self-reported physician diagnosis of asthma and at least one of the following allergic comorbid conditions: chronic hives, nasal allergies, hay fever, atopic dermatitis, dermatitis, eczema, or skin allergies. Patients were grouped by asthma control using their scores on the Asthma Control Test (ACT; scores ≤15: very poorly controlled, 16-19: not well-controlled and 20-25: well-controlled asthma). HRQoL was assessed with the physical component summary score (PCS), mental component summary score (MCS), and SF-6D health utilities derived from the SF-12v2 and SF-36v2. Generalized linear models, controlling for covariates (i.e., demographics and health characteristics), examined whether HRQoL differed by asthma control. Adjusted means and p-values were reported from these models.

RESULTS: Patient mean age was 49.8 years (SD=15.4), 66.3% were female and 75.9% were white. Among all patients, 29.3% (n=563) had very poorly controlled, 25.1% (n=482) had not well-controlled, and 45.7% (n=878) had well-controlled asthma. Very poorly controlled asthma patients relative to not well-controlled and well-controlled asthma patients had lower MCS (adjusted means=42.59 vs. 45.61 and 48.12), PCS (38.27 vs. 42.73 and 45.14) and health utilities (0.611 vs 0.655 and 0.698), all p<0.001. These differences exceeded minimally important differences (MIDs) of 3 points for MCS and PCS and 0.041 points for health utilities. Not well-controlled patients also had significantly lower MCS, PCS, and health utilities compared with well-controlled patients, however only health utilities reach MIDs threshold.

CONCLUSIONS: Over half (~55%) of all of the allergic asthma patients on ICS and LABA had uncontrolled asthma. Lower levels of asthma control were associated with lower HRQoL among allergic asthma patients treated with ICS and LABA.

CLINICAL IMPLICATIONS: The substantial number of uncontrolled allergic asthma patients on ICS and LABA suggests that clinicians may not be following the National Heart, Lung, and Blood Institute’s guidelines to step up therapy. Clinicians should consider stepping up therapy for these patients as findings imply that improving asthma control among allergic asthma patients on ICS and LABA could potentially lead to clinically meaningful improvements on HRQoL.

DISCLOSURE: Brandee Paknis: Employee: I am an employee of Novartis Pharmaceuticals Corporation, which funded this study. Lulu Lee: Consultant fee, speaker bureau, advisory committee, etc.: I am an employee of Kantar Health, which received funding from Novartis Pharmaceutical Corporation to conduct this study. Engels Obi: Employee: I am an employee of Novartis Pharmaceuticals Corporation, which funded this study. Abhishek Kavati: Employee: I am an employee of Novartis Pharmaceuticals Corporation, which funded this study. Bradley Chipps: Consultant fee, speaker bureau, advisory committee, etc.: I am a paid consultant of Novartis Pharmaceuticals Corporation, which funded this study.

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543